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Mechanisms for the formation of glycoxidation products in tions such as dialysis-related amyloidosis [1], bone re-
end-stage renal disease. sorption [2], and atherosclerosis [3], leading some au-
Background. Advanced glycation end products (AGEs) ac- thors to suggest that they represent a newly recognizedcumulate on tissue and plasma proteins in patients with renal
uremic toxin [4, 5]. The quantities of AGEs accumulatingfailure far in excess of normal aging or diabetes. The aim of
on tissue and plasma proteins in patients with renal fail-these studies was to elucidate the nature of the precursors and
the pathways that lead to an accelerated formation of two ure are far in excess of normal aging or diabetes [6, 7].
structurally identified AGEs [pentosidine and Ne(carboxy- Levels are unrelated to the concomitant presence or ab-
methyl)lysine (CML)] in the uremic milieu. sence of diabetes [3, 8–11]. The loss of renal mass is associ-Methods. Serum levels of the glycoxidation products, pen-
ated with increased accumulation of protein-bound circu-tosidine and CML, were quantitated by high-performance liq-
lating AGEs or their reactive fragments [7]. The renaluid chromatography in uremic patients treated by dialysis. The
formation of early glycation products (as furosine) and late tubule has been shown to process AGE-rich proteins
glycoxidation products was modeled in uremic serum and in [12] and to clear circulating free pentosidine [13]. Thus,
spent peritoneal dialysate.
the mechanisms responsible for accumulation of AGEsResults. Clinical factors that affect circulating levels of AGEs
in renal failure remain poorly defined and are likely toincluded dialysis clearance and dialyzer membrane pore size,
but not the presence or absence of diabetes. Both pentosidine be unique.
and CML form at an accelerated rate in serum from uremic In clinical research, immunoreactive AGE proteins
patients. Chelating agents most effectively slow the formation often are studied using antibodies of unknown specificity
in vitro. In uremic fluids, the primary mechanism of formation
[7]. Several AGE products are chemically and structur-of pentosidine is through the Amadori pathway. The primary
ally defined. The presence of glycoxidation products suchmechanism of formation of CML is through metal-chelated
autoxidation of reducing sugars generating reactive carbonyl as pentosidine [14], Ne(carboxymethyl)lysine (CML) [15],
precursors. In uremic serum, the presence of an unidentified and imidazolones [16] on specific tissue and circulating
reactive low molecular weight precursor accelerates the forma- proteins is associated with disease processes. A recent re-tion of pentosidine.
view explores the role of specific chemically defined AGEsConclusions. The formation of the two glycoxidation prod-
in uremic toxicity in greater detail than is possible in thisucts, pentosidine and CML, proceeds by different pathways
and is enhanced by different precursors in the uremic milieu. report [3]. The biochemical relationship between glucose
The formation of both AGEs is markedly enhanced by metal- and the glycoxidation products examined in this study
catalyzed reactions, evidence for the presence of increased is summarized in Figure 1. Both pentosidine and CMLmetal-ion mediated oxidant stress in uremia.
can form through metal-catalyzed oxidation of glucose or
Amadori products or ascorbate oxidation [17–19]. Glyoxal
and methylglyoxal are reactive intermediates generatedAdvanced glycation end products (AGEs) have been
during glycation reactions under oxidative conditions.associated with the pathophysiology of uremic complica-
Methylglyoxal also originates from triose phosphate me-
tabolism. Glyoxal is a particularly important precursor
for CML, which arises from both glycoxidation and lipox-Key words: pentosidine, Ne(carboxymethyl)lysine, advanced glycation
end products, high flux dialysis, uremia. idation reactions [20, 21]. The generation of glycoalde-
hyde, another precursor for CML formation, occurs viaReceived for publication April 21, 1999
the myeloperoxidase pathway [22, 23]. In contrast, pen-and in revised form November 10, 1999
Accepted for publication January 2, 2000 tosidine can form only from reducing sugars or ascorbate
oxidation products [17, 18].Ó 2000 by the International Society of Nephrology
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Fig. 1. Biochemical relationships among the products assayed in this study.
The two major treatment modalities for end-stage re- land, OH, USA). Patients are referred to CDC, a not-
for-profit, free-standing dialysis unit not affiliated withnal disease (ESRD), hemodialysis (HD) and peritoneal
dialysis (PD) differ with respect to their clearance of any national chain, from the Affiliated Hospitals of Case
Western Reserve University. Patients treated by PD (N 5free pentosidine and levels of protein-bound pentosidine
[8, 9, 24]. As determined by enzyme-linked immuosor- 28) were recruited from the PD Unit at University Hospi-
tals of Cleveland (UHC; Cleveland, OH, USA). Patientsbent assay (ELISA) techniques, circulating levels of low
molecular weight (LMW) AGE peptides reflect inade- with diabetes and diabetic nephropathy (indicated by
proteinuria) were recruited from the Renal Clinic atquate removal by dialysis [7]. However, the pentosidine
and CML present in serum exist as more than 95% bound UHC (N 5 24). Healthy control subjects were recruited
in response to a description of the study posted in workto circulating albumin, with less than 2% in LMW free
forms [9–11]. These apparently disparate observations areas of UHC (N 5 24). A signed, written consent was
obtained from all of the study patients and control sub-suggest that a dynamic equilibrium may exist between
AGEs linked to proteins too large for clearance by dial- jects in accordance with the guidelines of the Institutional
ysis and a LMW reactive precursor or catalyst. The goals Review Board, UHC. Whole blood was obtained from
of this project were twofold: (1) to examine the relation- patients immediately before the HD treatment or PD
ship between the pentosidine and CML content of circu- exchange. After clotting, serum was separated and stored
lating proteins, and demographic and prognostic mark- at 2808C until assay for pentosidine and CML. Sera
ers, in a large group of patients with ESRD; and (2) to from a subgroup of normals and patients treated by HD
elucidate the precursors, and the pathways, that lead to and PD was fractionated into high molecular weight
the accelerated formation of pentosidine and CML in (HMW) and LMW fractions for assay of the Amadori
the uremic milieu. product fructose-lysine (furosine method). All patients
with ESRD had been treated with their respective dial-
ysis modalities for at least six months prior to study.
METHODS
Clinical data and contemporaneous clinical laboratory
Patients data were obtained by chart review. All clinical labora-
tory results recorded from chart review represented val-Patients (N 5 194) treated by HD were recruited at
the outpatient Center for Dialysis Care (CDC; Cleve- ues measured in the clinical laboratory of UHC by stan-
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Table 1. Patient characteristics of donors to the pooled sera
Number Sex Age years Hemodialysis CML Pentosidine
of donors M/F (range) Diabetes membrane pmol/mg protein pmol/mg protein
Uremic (PD)
Pooled serum 5 3/2 61 (53–72) 3 172.3 13.3
Uremic (HD)
Pooled serum #1 5 3/2 48 (22–65) 2 3 F80/2 F8 130.2 17.6
U. pool #2 6 2/4 55 (33–80) 1 3 F80/2 F8 174.1 24.5
U. pool #3 8 4/3 51 (20–85) 3 6 F80/2 F8 161.1 22.6
U. pool #4 16 5/11 63 (33–82) 7 10 F80/6 F8 167.5 21.4
U. pool #5 14 6/8 54 (19–83) 4 10 F80/4 F8 172.2 25.0
Control pooled
Serum #1 5 2/3 48 (46–50) 0 66.8 1.4
C. pool #2 7 3/4 40 (21–52) 0 84.2 1.5
C. pool #3 10 5/5 43 (26–54) 0 66.6 1.6
C. pool #4 5 2/3 43 (30–50) 0 75.9 1.5
C. pool #5 7 4/3 42 (30–52) 0 72.7 1.7
dard autoanalyzer techniques. All patients treated by USA) and reconstituted with the addition of specific
reagents. Serum or pooled spent peritoneal dialysateHD used dialysis membranes made of polysulfone: The
F8 “high-efficiency” dialyzer was contrasted with the F80 with added HSA was incubated at 378C under the condi-
tions specified later in this article, and at each time point,“high-flux” dialyzer (Fresenius). The average pore size
of the F8 membrane is 14 A˚ (average urea clearance an aliquot was processed for the measurement of the
Amadori product fructose-lysine (furosine method) orapproximately 154 L/week), and the F80 membrane, 31 A˚
(average urea clearance approximately 170 L/week). By AGEs as described.
comparison, the living peritoneal membrane has an esti-
AGE formation in serum and pooled spent peritonealmated average pore size of 40 to 200 A˚, with an average
dialysate exposed to high glucoseurea clearance of 50 to 75 L/week [25].
To determine the role of glycoxidation in the forma-
Sample preparation for in vitro incubations tion of AGEs, pools of patient sera and spent dialysate
To achieve adequate volumes of serum and to provide were incubated at a pharmacological level of glucose (0.5
a stable baseline in experiments generating multiple re- mol/L) designed to maximize the formation of Amadori
sults, the in vitro experiments were performed using a precursor on proteins. The glucose level was determined
pool of serum from multiple donors. Whole blood was in each pooled serum and in whole (unconcentrated)
collected in trace metal-free tubes (Vacutainert; Becton pooled spent dialysate. Glucose was then added to reach
Dickinson, Mountain View, CA, USA) from groups of 0.5 mol/L. The samples were sterile filtered and incu-
medically stable patients or healthy control individuals bated in a sterile aerobic environment with 5% CO2 at
and allowed to clot. Specific information about the sub- 378C for up to 28 days, in the absence of phosphate-
jects who contributed to collections used in in vitro stud- buffered saline to avoid the addition of metal ions. The
ies is summarized in Table 1. Serum from the collections native buffering capacity of serum and spent dialysate
was pooled according to patient or control groupings. A resulted in the maintenance of a constant pH of 7.4
pool of spent peritoneal dialysate was created from the throughout the incubations, as tested by pH strip (What-
first morning drain of 20 uninfected patients treated by man International, Maidstone, UK) at the end of each
PD and used throughout the in vitro experiments. Be- incubation period.
cause the protein concentration of spent peritoneal dialy-
Effects of inhibitors of AGE formationsate is very low, in some experiments, normal human
serum albumin (HSA; Albumarce 25% solution for hu- To determine the mechanism of accelerated formation
of AGEs in uremic fluids in the presence of 0.5 mol/Lman injection; Baxter Healthcare, Glendale, CA, USA;
or 99% essentially fatty acid free, essentially globulin- glucose, the incubation experiments were conducted
with a second pool of serum from healthy subjects andfree albumin; Sigma, St. Louis, MO, USA) was added
to bring the content to 65 mg/mL, comparable to serum. patients treated by HD and in pooled spent peritoneal
dialysate with added HSA. In these and all subsequentA control experiment was performed incubating unal-
tered HSA (without added phosphate buffer) under aer- in vitro experiments, serum from patients treated by PD
was excluded. In pools 2 through 5, uremic serum wasobic conditions at 378C for up to 20 days. In some experi-
ments, the dialysate was concentrated by freeze drying obtained from patients treated by HD only. Incubations
were carried out with the addition of either chelating(Virtis Freezemobile II; Virtis Company, Gardiner, NY,
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agents diethylenetriamine pentaacetic acid [DTPA (1 mmol/L to reproduce normal serum), or ascorbate (100
mmol/L to reproduce normal serum levels) [26].mmol/L) and phytic acid (1 mmol/L)] to block the cata-
lyzing effect of metals, aminoguanidine (5 mmol/L) to
Pentosidine and CML formation in LMW and HMWtrap carbonyl intermediates, catalase (500 units added
fractions of pooled spent peritoneal dialysatedaily) to block the effect of H2O2 or heat inactivation
Based on the kinetics of formation of Amadori prod-at 558C for 30 minutes (to block any activity of serum
uct, the LMW and the HMW fractions of pooled spentenzymes), in an aerobic environment plus 5% CO2 at
peritoneal dialysate were incubated for 10 days without378C for periods of up to 20 days.
the addition of reducing sugars to demonstrate the pres-
Formation of oxaldehydes/dicarbonyl compounds ence or absence of a naturally occurring precursor for
pentosidine or CML formation. In these experiments,To trap and identify the dicarbonyl compounds formed
100 mmol/L l-lysine (Bachem Bioscience, Inc.) wereas triazine derivatives, aliquots of the incubations per-
added to serve as a direct precursor of CML. The LMWformed in the presence of 5 mmol/L aminoguanidine
and HMW fractions were also incubated with addedwere analyzed with a Hewlett-Packard HP8590 Ga Chro-
HSA as described previously in this article. To thesematography/Mass Spectroscopy instrument (GC/MS;
incubation mixtures, glucose or 100 mmol/L lysine wasHewlett Packard, Wilmington, DE, USA) after extraction
added to demonstrate the effects of precursors in catalyz-and derivatization with trimethyl silyl reagent (TMS). Sec-
ing AGE formation on HSA.ondary ion monitoring was used to detect the aminotri-
azine of 3-deoxyglucosone (m/z 5 398), glucosone (m/z 5 CML formation in aqueous and lipid-soluble fractions
270), glyoxal (m/z 5 168), and methylglyoxal (m/z 5 182). of pooled spent peritoneal dialysate
To determine whether lipid precursors contribute toPentosidine and CML formation in LMW and HMW
the formation of CML in pooled spent peritoneal dialy-fractions of uremic serum
sate, chloroform-ethanol extraction was performed. ABecause dialysis modality affects circulating levels of
103 concentrated sample of pooled spent PD was sub-pentosidine and CML differently, pooled serum from
mitted for free fatty acid determination. Whole dialysatepatients treated by HD was separated into HMW and
was freeze dried and reconstituted to 23 in MilliQ (metalLMW fractions using a 10,000 MW cut-off filter (Amicon,
ion-free) sterile water. An extraction procedure was used
Inc., Beverley, MA, USA). Experiments were repeated
that has been designed to remove all nonesterified and
three times using three different pools of serum (pools
trigycleride fatty acids [27]. Briefly, a 3:1 mixture of chlo-
2 through 5) from patients on HD and normal controls roform:methanol was added to the pooled spent perito-
(Table 1). neal dialysate in a 4:1 ratio and vigorously mixed using
Whole serum pools, LMW, and HMW fractions were a vortex. The fractions were separated by centrifugation
incubated for 10 days without the addition of reducing at 2500 r.p.m. for 20 minutes at 258C. Each of the frac-
sugars to demonstrate the presence or absence of a natu- tions was dried down and then reconstituted in 1 3 PBS
rally occurring precursor for pentosidine or CML forma- with 65 mg/mL of HSA. The extracted fractions with
tion. The HMW fraction was obtained by dialyzing whole added HSA were incubated for up to 14 days.
serum using 10,000 molecular weight cut-off Dispo Dia-
lyzers (Spectrapor, Laguna Hills, CA, USA) in sterile, Assays
chelated (Chelex-100 Resin, Biotech Grade; Bio-Rad Lab, Serum and dialysate glucose levels were measured by
Hercules, CA, USA) phosphate-buffered saline (PBS) the clinical laboratory at UHC using an autoanalyzer
at 48C. Dialysis was carried out in plastic, never-before- method. Serum and dialysate total protein was assayed
used containers with three changes of PBS over four in a microassay modification of the Bradford method
days. Incubations were performed adding the LMW frac- using Coomassie brilliant blue [9, 28]. Amadori product
tion of HD serum to the HMW fraction of normal serum. or AGEs were measured by high-performance liquid
Control incubations consisted of the HMW weight frac- chromatography using previously published methods:
tions of normal and uremic serum reconstituted with furosine, a stable hydrolysis product of the Amadori
PBS in place of the LMW fraction. compound fructose-lysine, according to the method of
In addition, the LMW fraction of HD serum was incu- Wu, Monnier, and Friedlander [28]; pentosidine, ac-
bated with or without 100 mmol/L Na-acetyl lysine-argi- cording to a modification of the method of Friedlander
nine peptide (Lys-Arg; a substrate for pentosidine for- et al and Odetti et al [9, 29]; and CML, according to the
mation; Bachem Bioscience, Inc., King of Prussia, PA, method of Glomb and Monnier and El Gawish et al
USA), in the presence or absence of ribose (100 mmol/L, [22, 30]. The processing of serum, serum fractions, or
as a positive control for the formation of pentosidine, peritoneal dialysate for the measurement of free furo-
sine, pentosidine, or CML is based on a modification ofat previously described concentration) [17], glucose (10
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Table 2. Pentosidine and Ne(carboxymethyl)lysine content (pmol/mg protein) of circulating proteins (pmol/mg protein)
in patient and control groups
DiabeticF8 F80 PD
with normal
Group diabetic non-diabetic diabetic non-diabetic diabetic non-diabetic kidney function Control
N 51 46 60 45 7 21 24 24
Pentosidine 26.3c 27.7c 20.3 21.9 17.6b 16.8b 3.9a 1.4a
SEM 1.5 1.8 1.3 1.4 4.7 1.9 0.9 0.1
CML 317.3 298.9 286.2 255.8 247.6 291.1 44.9a 76.7a
SEM 13.8 13.8 11.6 8.6 16.8 17.7 4.6 4.9
aP , 0.0001 control or diabetes compared with all ESRD
bP , 0.001 PD compared with F8
cP , 0.001 F8 compared with F80
Table 3. Multiple regression analysis of covariates for thethe methods of Takahashi et al [31, 32], as previously
pentosidine and Ne(carboxymethyl)lysine content of circulating
described [9, 33], whereby the LMW fractions are not proteins in 222 patients with ESRD
subjected to acid hydrolysis before injection on the high-
Pentosidine CMLperformance liquid chromatography (HPLC).
Variable t value P value t value P value
Calculations and statistical methods Duration ESRD months 6.391 ,0.0001 2.238 0.0264
Type of dialysis 3.233 0.0014 0.601 NSSimple and multiple regression analyses were used to BUN 2.795 0.0057 2.310 0.0220
determine relationships between pentosidine or CML Uric acid 2.253 0.0253 0.931 NS
Cholesterol 0.551 NS 0.622 NSand other parameters both in specific patient groupings
Ferritin 0.980 NS 1.652 NSand the study population as a whole. Between-group Iron 0.711 NS 0.041 NS
comparisons in parametric data were performed by anal- Albumin 0.002 NS 0.650 NS
Diabetic status 0.597 NS 0.552 NSysis of variance (ANOVA), with pair-wise comparisons
Age 0.501 NS 1.792 0.0748by Fisher’s PLSD, or by individual t-test where appro- Sex 1.494 NS 0.384 NS
priate. Significance was determined by a P value of less Race 0.974 NS 0.546 NS
than 0.05. Data analysis was performed using StatView NS, no significant difference.
5.0 (SAS Institute, Inc., Cary, NC, USA) working on a
Macintosh Centris 650.
with normal renal function (whether diabetic 44.8 6 4.8
RESULTS or healthy 76.7 6 4.6), the mean CML levels (pmol/mg
protein) did not differ among the three groups of patientsCirculating levels of pentosidine and CML:
treated for ESRD: F8 (N 5 93), 308.7 6 9.7; F80 (N 5Comparison of dialysis modalities
101), 273.8 6 7.8; PD (N 5 28), 287.3 6 10.2 (P 5 NS).A dramatic increase in the AGE content of circulating
The slightly lower CML levels in diabetic patients withproteins in patients with ESRD was confirmed in these
normal kidney function versus healthy control subjectsstudies. Pentosidine levels were 15- to 25-fold greater,
did not reach statistical significance in ANOVA (Table 2).and CML levels were fivefold to sixfold greater than
As previously reported and as shown in Table 2, therelevels in patients with diabetes and proteinuria or healthy
were no differences between serum levels of pentosidinesubjects (Table 2). The high efficiency F8 dialyzer was
or CML in the diabetic and nondiabetic patients withused to treat 93 of the HD patients (49 diabetics and 44
ESRD [8–10].nondiabetics), and with the high-flux F80 dialyzer, 101
Multiple linear regression confirmed the lack of effectpatients were treated (56 diabetics and 45 nondiabetics).
of diabetic status in analysis of the patients with ESRDThere were 7 diabetics and 21 nondiabetics among the
(Table 3). Controls and diabetics with normal renal func-28 patients treated by PD. The mean pentosidine level
tion were excluded from this analysis. For pentosidine,(pmol/mg protein) in the 93 HD patients treated by F8
the overall probability of an analysis with 12 independentdialyzers was 27.0 6 1.2; the 101 HD patients treated by
variables was P , 0.0001 (R2 5 0.296). For CML, theF80, 20.9 6 0.9; the 28 patients treated by PD, 16.9 6 1.8;
probability was P 5 0.05 (R2 5 0.105). Regressors withdiabetics with proteinuria 3.8 6 0.9 and healthy controls
significant influence on the pentosidine content of circu-1.4 6 0.1. By ANOVA, all pair-wise comparisons were
lating proteins were length of time treated for ESRD,at P , 0.0001 with the exception of the comparison
type of dialysis treatment (F8, F80, or PD), predialysisof diabetics and healthy controls (P 5 NS). Although
markedly elevated compared with levels found in subjects blood urea nitrogen (BUN), and uric acid. Regressors
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Fig. 2. Free furosine in the low molecular weight (LMW) fraction of
serum from patients with end-stage renal disease (ESRD) treated by
hemodialysis (HD) with F8 or F80 dialysis membranes or by peritoneal
dialysis (PD). Patients with diabetes (3) compared with patients with-
Fig. 3. Furosine formation in serum proteins from normal controls (s),out diabetes (s).
patients on HD (j), and patients on PD (m) incubated in 0.5 mol/L
glucose for the time indicated. Normal human serum albumin (HSA)
was added to spent, pooled peritoneal dialysate (,) to bring the protein
concentration of the dialysate into the range of the serum (65 mg/mL).
Parallel incubations in 0.5 mol/L glucose were performed simultaneouswith influence on the CML content of circulating pro-
with the serum incubations. The arrow points to a plateau in formationteins were the duration of ESRD and the predialysis
reached by normal serum and HSA added to the pooled spent dialysate.
BUN. In contrast to pentosidine, no effect of dialysis
treatment modality was found for CML.
Fructose-lysine (furosine method) in LMW and HMW
normals (38 6 4 pmol/mL, N 5 6, P , 0.02 normal versusfractions of serum
uremic groups by ANOVA). In each dialysis group, the
As previously reported, the serum protein content of diabetic patients had higher levels of free furosine than
the Amadori product fructose lysine (furosine method) the patients without diabetes (P , 0.003 diabetic vs.
was not increased in renal failure in the absence of diabe- nondiabetic).
tes (Fig. 2) [9]. However, in contrast to the pattern seen
for the glycoxidation products, the serum proteins from Glucose autoxidation and glycoxidation in the
patients with diabetes contained larger quantities of fruc- uremic milieu
tose-lysine (furosine) than serum proteins from patients In support of our use of serum pooled from patients
without diabetes [8, 9]. The fructose-lysine content of on HD and normal controls, a comparison of the various
the HMW fraction of serum was similar to whole serum, pools demonstrated no major difference in donor charac-
with higher levels found in patients with diabetes. No teristics or baseline levels of pentosidine and CML (Ta-
differences were identified in the fructose-lysine content ble 1). HSA (Albumarc), incubated for 20 days at 378C in
of the HMW fractions of serum by dialysis modality: (1) an aerobic environment with 5% CO2 without additives,
patients treated by HD with F8 (628 6 116 pmol/mg showed no change in levels of protein-bound pentosidine
protein, N 5 8), (2) patients treated by HD with F80 (3.38 to 3.67 pmol per mg protein) or CML (410 to 408
(592 6 128, N 5 7), (3) patients treated by PD (422 6 pmol/mg protein).
44, N 5 10), and normals (503 6 29, N 5 6). Significantly, The initial kinetics of formation of the protein-bound
there was a higher concentration of free fructose lysine Amadori product fructose-lysine (furosine method) were
(as furosine) in the LMW fraction of serum (pmol/mL) comparable in uremic serum (HD and PD) and spent
from patients treated by HD with F8 (845 6 307, N 5 8), pooled dialysate in the presence of 0.5 mol/L glucose
by HD with F80 (487 6 181, N 5 7), and by PD (314 6 (Fig. 3). After 15 days, a plateau for furosine was reached
in both the normal serum and the pooled peritoneal113, N 5 10), compared to the serum LMW fraction of
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Fig. 4. Formation of pentosidine (A) and
Ne(carboxymethyl)lysine (CML; B) in 0.5
mol/L glucose-incubated serum proteins from
normal controls (s), patients on HD (j), pa-
tients on PD (m), and spent, pooled peritoneal
dialysate (,) under identical incubation con-
ditions, as in Figure 3. (C) Free pentosidine
and (D) free CML formation in the protein-
free fractions of these incubations.
dialysate with added HSA (arrow), but further increases the incubation mixtures (Fig. 4 C, D). For both types of
free AGE, the highest concentrations were attained inin Amadori product (as furosine) were seen in the serum
from patients treated by HD and PD. serum from patients on HD. Free pentosidine was higher
at baseline in serum from patients on HD than in serumThe determination of the glycoxidation products pen-
tosidine and CML in the same incubations led to quite from those on PD and in normal control serum. Free
CML levels, in HD and PD serum, were higher than normalunexpected results. In contrast to formation of the Ama-
dori product fructose-lysine (furosine method), pentosi- control serum. In contrast to the accelerated formation of
protein-bound CML on HSA in pooled peritoneal dialy-dine accumulation occurred at both a more rapid rate
and reached a higher level on serum proteins from pa- sate, there was very little free CML in the presence of
HSA under the same incubation conditions. More freetients on HD and PD than in the concomitant incuba-
tions of normal serum or pooled spent dialysate with CML . free pentosidine was detected during incubations
in serum compared with incubations involving the addi-added normal HSA (Fig. 4A). There was a dramatically
accelerated formation of CML on HSA in the presence tion of HSA to pooled spent peritoneal dialysate.
of pooled spent peritoneal dialysate (Fig. 4B). However,
Effects of specific inhibitors of the Maillard reactionthe CML formation rate proceeded at parallel and equal
rates in serum from HD, PD, and normals. Thus, substan- In normal serum, pentosidine formation in the pres-
ence of 0.5 mol/L glucose was most strongly inhibitedtial differences in the kinetics of formation of pentosidine
and CML were seen when comparing the normal and by chelators and catalase, suggesting a role for redox
active metals (Fig. 5A). Aminoguanidine blocked CMLuremic (HD or PD) serum samples. Clearly, the mecha-
nism of formation of CML in spent peritoneal dialysate formation in normal serum, but had no effect on pentosi-
dine formation (Fig. 5B). In contrast to their effect ondiffered from the mechanism of formation of pentosidine.
Parallel with the accumulation of AGEs on proteins, pentosidine formation, chelating agents and catalase did
not inhibit CML formation in normal serum. In mostboth free pentosidine and free CML were generated in
Weiss et al: AGE formation in ESRD2578
Fig. 5. Effect of inhibitors on advanced glycation end product (AGE) formation in 0.5 mol/L glucose (serum proteins from normal controls,
patients on HD and on HSA added to pooled spent peritoneal dialysate). (A, C, E ) Pentosidine. (B, D, F ) CML. Symbols are: (s) control
condition; (h) chelating agents (1 mmol/L DTPA, 1 mmol/L phytic acid); (n) aminoguanidine (5 mmol/L); (e) catalase (500 U/day); (1) treatment
by heating. Chelation provided the most effective inhibition of CML and pentosidine formation in uremic fluids.
experiments, heat inactivation followed the pattern of tosidine in this model system (Fig. 5E). Chelating agents
had a dramatic effect on suppression of CML formationcontrol values, suggesting the absence of serum enzymes
that catalyze or prevent glycoxidation. The pattern of (Fig. 5F). Aminoguanidine and catalase were less effec-
tive in blocking CML formation on HSA added to pooledinhibition of pentosidine formation in serum from pa-
tients treated by HD was similar to that of normal, with spent peritoneal dialysate.
the greatest suppression of formation in the presence
Aminoguanidine induced a-dicarbonyl compoundsof chelators and catalase (Fig. 5C). In contrast, CML
formation in uremic serum was suppressible by amino- To further investigate the mechanisms of formation
of pentosidine and CML in uremic fluids, incubationsguanidine and, to an even greater degree, by chelating
agents (Fig. 5D). These observations reveal a fundamen- performed in the presence of 5 mmol/L aminoguanidine
and 0.5 mol/L glucose were subjected to GC/MS to quan-tal difference in the mechanism of CML formation in
normal serum compared with uremic serum, emphasiz- titate triazine derivatives [34]. A typical chromatogram of
aminoguanidine triazines formed in the presence of spenting the catalytic role of redox active transition metals.
A role for redox active metals was even more obvious in peritoneal dialysate is shown in Figure 6. The triazines of
3-deoxyglucosone, glyoxal, methylglyoxal, and glucosonethe incubations in peritoneal dialysate. Chelating agents
and catalase had the greatest suppressive effect on pen- were detected and found to increase with incubation time
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Fig. 6. Representative gas chromatography/mass spectrum (GC/MS) chromatogram of aminotriazines formed in pooled spent peritoneal dialysate
incubated for 14 days in the presence of added human serum albumin (HSA; 75 mg/mL), 0.5 mol/L D-glucose, and 5 mmol/L aminoguanidine.
Each triazine was quantitated using selective ion monitoring, as described in the Methods section.
Fig. 7. Formation of aminotriazines on incu-
bation with glucose (0.5 mol/L) and amino-
guandine (5 mmol/L) in serum from healthy
control subjects (s), in serum from uremic pa-
tients treated by HD (d), and in pooled spent
dialysate with added HSA (h). Serum from
HD has greater initial levels of 3-deoxygluco-
sone-triazine (A). Glucosone-triazine, glyoxal-
triazine and methylglyoxal-triazine all increase
to the greatest peak levels in pooled spent
dialysate (B–D).
in all the specimens (Fig. 7). As previously reported for The pattern of increase in 3-deoxyglucosone-triazine was
similar throughout the incubations. In contrast, the peak3-deoxyglucosone [35], the baseline levels were 10-fold
greater than normal in uremic serum and 5-fold greater methylglyoxal-, glyoxal-, and glucosone-aminotriazine
levels were twofold to fourfold greater in the pooledthan normal in pooled spent peritoneal dialysate (Fig.
7A). Baseline levels of methylglyoxal-, glyoxal-, or glucox- spent peritoneal dialysate than in the uremic or normal
serum, suggesting the presence of intense metal-cata-one-aminotriazine were not increased in spent peritoneal
dialysate, in contrast to fresh heat-sterilized dialysate [36]. lyzed glucose autoxidation in this uremic fluid.
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Fig. 8. Triplicate incubation experiments in pools of normal and uremic serum with added glucose and ascorbate. (Top panels) Pentosidine. Note
the difference in scales for pentosidine (normal vs. uremic). All uremic conditions greater than normal (P , 0.0001). Letters in A and B are: a,
different from day 0, P , 0.0001; b, different from day 10, P , 0.001; c, different from day 10, P , 0.01. In C and D, there was no difference
between uremic and normal CML values. Letters in C and D are: a, different from day 10, P , 0.0001; b, different from day 10, P , 0.001; c,
different from day 0, P , 0.01.
Spontaneous formation of AGEs: Comparison of or ascorbate was identical. There was no spontaneous
HMW and LMW fractions of serum change in the pentosidine or CML content of HMW
fractions (.10,000 MW) of either uremic or normal se-In vivo studies established a role for dialysis in circulat-
rum over the 10 day incubation period (data not shown).ing levels of AGEs. Therefore, experiments were per-
However, in separate experiments, when the LMW frac-formed to investigate the possible presence of a reactive
tion of uremic serum was added to the HMW fractionprecursor of AGE formation in the LMW and the HMW
of normal serum, there was a tenfold increase in thefractions of serum. In the initial experiments, whole se-
pentosidine content (1.3 6 0.1 to 14.6 6 0.2 pmol/mgrum was incubated without additives at 378C. Serum
protein), which was not further catalyzed by added glu-pools 3 through 5 were used in these experiments. The
cose or ascorbate (data not shown). In contrast, therepentosidine content of serum proteins doubled within
was only a twofold increase in the CML content (80.6 610 days in both normal (2.1 6 0.4 to 5.3 6 0.1 pmol/mg
1.5 to 168 6 14 pmol/mg protein) of proteins, with aprotein) and uremic serum (24.8 6 1.9 to 53.5 6 1.9
dramatically increased catalysis of CML formation inpmol/mg protein; Fig. 8 A, B). In contrast, the CML
response to added glucose (to 2240 6 36 pmol/mg proteincontent of serum proteins increased only slightly (about
in the presence of 0.5 mol/L glucose). These data under-50 pmol/mg protein) in both normal serum (73 6 4 to
score the important contribution of the LMW fraction126 6 2) and uremic serum (167 6 4 to 231 6 2; Fig.
of both uremic and normal serum to the in vitro forma-8 C, D). In addition, the pattern of CML formation in
normal and uremic serum upon the addition of glucose tion of glycoxidation products in serum. The data also
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Table 4. Concentration of pentosidine and Ne(carboxymethyl)lysine in low molecular weight (LMW) fraction
of normal and uremic serum (pmol/mL)
Pentosidine Ne(carboxymethyl)lysine
LMW fraction LMW fraction LMW fraction LMW fraction
Condition normal serum uremic serum normal serum uremic serum
Day 0 ND 33.9 ND 93
Day 0 1 100 mol/L Lys-Arg ND 32.9 ND 165
Day 10 ND 38.3 ND 203
Day 10 1 100 mmol/L Lys-Arg 57.0 176.9 ND 334
1 10 mmol/L glucose 1 100 mmol/L Lys-Arg 73.3 176.4 ND 516
1 100 mmol/L ascorbate 1 100 mmol/L Lys-Arg 121.2 209.7 ND 521
1 10 mmol/L glucose ND 41.2 ND 138
1 100 mmol/L ascorbate ND 33.7 ND 173
Control incubations in 1 3 PBS at 10 days
1 100 mmol/L ribose 1 100 mmol/L Lys-Arg 73,856.4 161,292
1 100 mmol/L ascorbate 1 100 mmol/L Lys-Arg 42.3 430
1 mmol/L Lys-arg ND 91
ND is not detected.
demonstrate that pentosidine formation proceeds at a idine increased from 18.1 6 2.1 to 33.4 6 3.3 (no differ-
ence from control) and CML from 1341 6 187 to 10,678 6much greater rate than CML formation in uremic serum
248 pmol/mL in the LMW fraction.or the LMW fraction of uremic serum added to HMW
proteins.
CML formation in aqueous and lipid-soluble fractions
of pooled spent peritoneal dialysateFormation of glycoxidation products in LMW
fractions of uremic serum Ne(carboxymethyl)lysine can form through lipid per-
oxidation as well as glycoxidation reactions [21]. To ex-To further elucidate the nature of the AGE-forming
amine the role of lipids in CML formation, free fattyactivity of the LMW fraction, the latter was incubated
acids were removed from pooled spent peritoneal dialy-with and without the dipeptide Lys-Arg as a trapping
sate with chloroform-methanol extraction [27]. Twoagent for the precursors of pentosidine and CML. At 10
sources of HSA, one containing lipid (Albumarc) thedays, in the presence of Lys-Arg, the concentrations of
other more than 99% fatty acid free (Sigma), were addedboth pentosidine and CML formation increased fivefold
to the dialysate fractions. With incubation, no increaseand threefold, respectively (Table 4). The LMW fraction
in the CML content of the HSA was seen in the presenceof uremic serum contained a precursor or catalyst that
of the reconstituted chloroform extracted fraction. Bothenhanced pentosidine formation compared with the
the whole and the delipidated aqueous fractions wereLMW fraction of normal serum. In contrast, the LMW
associated with an increase in CML, and the rate offraction of uremic serum had less enhancing effect on
increase was not higher in the Sigma HSA (Fig. 9A).the formation of CML, and the LMW fraction of normal
However, the rate of increase was higher in the fattyserum contained no catalytic effect on CML under any
acid-free HSA (Fig. 9B). The incubation of these frac-incubation condition.
tions with 0.5 mol/L glucose and HSA showed an in-As in the experiments using whole serum (Fig. 8),
creased rate of formation of CML (pmol/mg protein) inCML formation in the presence of Lys-Arg occurred
the presence of the aqueous fraction (305 to 4951 on HSA,more readily when physiological concentrations of glucose
733 to 12,930 on Sigma HSA) compared with wholeand ascorbate were added. These data strongly suggest
dialysate (293 to 3463 on HSA, 664 to 4289 on Sigmathat a precursor for CML formation must be generated
HSA) or the chloroform-extracted fraction (293 to 2141during incubation (most probably through oxidation),
on HSA, 720 to 2679 on Sigma HSA). Thus, the enhancedwhereas a precursor for pentosidine formation is already
CML-forming activity in pooled spent peritoneal dialy-
present in the LMW fraction of uremic serum. sate is not associated with lipid peroxidation. In addition,
the chloroform-soluble fractions of spent peritoneal dial-Formation of AGEs in LMW fraction of pooled spent
ysate suppress CML formation in the presence of 0.5peritoneal dialysate
mol/L glucose compared with the aqueous fractions.
Because pooled spent peritoneal dialysate catalyzed
the most dramatic increases in CML (Fig. 4B), on added
DISCUSSIONHSA, a naturally occurring precursor was sought in the
LMW (,10,000 MW) fraction of dialysate. In the pres- This study reveals several important new findings.
First, there is a significant association between the poreence of 100 mmol/L lysine, incubated for 10 days, pentos-
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Fig. 9. Formation of CML on HSA and delip-
idated HSA added to pooled spent peritoneal
dialysate. (A), HSA. (B) delipidated HSA.
Symbols are: (s) chloroform-soluble fraction;
(g) 50:50 mixture of chloroform soluble and
aqueous fractions of spent dialysate after lipid
extraction; (.) aqueous fraction of dialysate
after lipid extraction; (d), whole, unextracted
dialysate.
size of the dialysis membrane and circulating levels of nous renal clearance of AGEs as native renal function
declines or the accumulation of unmeasured precursorprotein-bound pentosidine, but not CML. In keeping
with this finding, the LMW fraction of uremic serum and substrate(s).
In this study, pentosidine differed from CML in thatspent pooled peritoneal dialysate contains a precursor
or catalyst for increased pentosidine formation. Second, the larger the “pore” size represented by the dialysis
modality, the lower its protein-bound levels (Table 2).chelating agents markedly inhibit the formation of gly-
coxidation products (CML..pentosidine) in uremic se- The lowest circulating levels of pentosidine were seen
in patients treated by PD, reflecting the unique clearancerum and spent peritoneal dialysate with added HSA.
Third, the CML-catalyzing activity of spent dialysate is of pentosidine-rich proteins by this living dialysis mem-
brane [8, 24]. LMW AGE peptides have been shown tosurprisingly in the delipidated aqueous fraction and not
in the reconstituted lipid-containing chloroform fraction. “catalyze” the formation of HMW AGE on calf collagen
in vitro [7], similar to the activity of the LMW componentFourth, glucose autoxidation conditions are present in
spent peritoneal dialysate, as evidenced by the increased of serum and dialysate in our in vitro studies. Thus,
increased clearance of a LMW precursor may explain theformation of glyoxal and glucosone-aminotriazines in the
presence of aminoguanidine. This enhanced generation differences in pentosidine seen in this study. Recently,
pentosidine levels were compared in patients treated byof precursors is the most likely explanation for acceler-
ated formation of chelation-inhibitable CML formation high-flux HD using a variety of membranes. Biocompati-
ble polysulfone was associated with a lower level of pen-in spent dialysate, rather than the presence of lipid perox-
idation products or polyunsaturated fatty acids. tosidine than less bioincompatible membranes such as
cellulose acetate [43]. These observations raise the ad-The dramatic acceleration of both pentosidine and
CML formation in ESRD is confirmed in these studies ditional issue that factors such as membrane-induced
alterations in the physiologic processing and removal[6, 33, 37, 38]. Collectively, AGE levels in ESRD were
5 to 25 times greater than levels seen in patients with of pentosidine from HMW proteins may contribute to
pentosidine levels in patients treated by HD [43].diabetes and normal renal function. In diabetes, the con-
trol of hyperglycemia is believed to be the major factor One dramatic observation was the spontaneous forma-
tion of pentosidine in serum, as previously reported byleading to deposition of AGEs [39–41], particularly pen-
tosidine [6], on tissue and plasma proteins. The data in Miyata et al [37, 44]. However, the addition of a range
of concentrations of ascorbate or glucose did not resultthis patient population confirm a previous observation
that serum levels of CML were slightly subnormal in in any further increase in the peak level of pentosidine
formation in uremic serum compared with normal serum.diabetic patients with normal renal function [42]. In our
patient population, the uremic state and its duration The existence of a precursor compound in the LMW
fraction of uremic serum was demonstrated by its abilityhad a greater impact on the AGE content of circulating
proteins than the diabetic status of the individual. This to catalyze the formation of pentosidine in response to
added Lys-Arg, but not added glucose or ascorbate.finding may result from the known decrease in endoge-
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The selective increase in pentosidine formation in se- als are tightly sequestered by binding proteins such as
albumin, ferritin, transferrin, and ceruloplasmin, a de-rum from uremic patients was not paralleled by an in-
creased rate of formation of any of the triazines. Baseline fense against their ability to function as radical genera-
tors in the Fenton reaction [49]. Recent data suggestslevels of 3-deoxyglucosone were increased in uremic se-
rum, as previously reported [35]. However, levels of 3- that CML may be implicated in binding of redox active
copper and the enhancement of oxidizing activity bydeoxyglucosone increased in parallel and to the same
degree in both uremic and nonuremic incubations in the uremic serum [50, 51]. These observations would explain
in part why chelating agents were more effective inhibi-presence of 0.5 mol/L glucose. These results suggest, as
previously described, that 3-deoxyglucose is not a major tors of CML formation in uremic than in normal serum
(Fig. 5).precursor of pentosidine or CML [44]. Surprisingly,
aminoguanidine had little inhibitory effect on pentosi- In conclusion, in vitro experiments demonstrate that
the primary mechanism of formation of CML is throughdine formation in uremic serum, suggesting that the im-
mediate pentosidine precursor is not a reactive carbonyl. metal-chelated autoxidation of reducing sugars generat-
ing reactive carbonyl precursors. In uremic serum, theHowever, this observation does not exclude labile dicar-
bonyls such as dehydroascorbate or 2,3-diketogulonate presence of an unidentified reactive LMW precursor ac-
celerates the formation of pentosidine. In the presence ofas precursors of reactive pentoses such as xylose serum
[17, 35]. Another likely precursor is arabinose, which renal failure, the formation of both CML and pentosidine
are markedly enhanced by metal-catalyzed reactions, ev-has been reported to be abnormally increased in uremia
[45, 46]. The strong glucose-antoxidizing conditions found idence for the presence of increased metal-ion–mediated
oxidant stress in uremia.in spent dialysate would favor its formation.
In contrast to pentosidine, CML formed only upon
addition of glucose or ascorbate. Because spent dialysate ACKNOWLEDGMENTS
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